TumCG Cancer Research Results

TumCG, Tumor cell growth: Click to Expand ⟱
Source:
Type:
Normal cells grow and divide in a regulated manner through the cell cycle, which consists of phases (G1, S, G2, and M).
Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. This can result from mutations in genes that control the cell cycle, such as oncogenes (which promote cell division) and tumor suppressor genes (which inhibit cell division).
Melanoma, Melanoma Skin Cancer: Click to Expand ⟱
Melanoma is a rare form of skin cancer. It is more likely to invade nearby tissues and spread to other parts of the body than other types of skin cancer.
Scientific Papers found: Click to Expand⟱
5437- AG,    Modulation of PD-L1 by Astragalus polysaccharide attenuates the induction of melanoma stem cell properties and overcomes immune evasion
- in-vivo, Melanoma, B16-F10
CSCs↓, CD133↓, BMI1↓, PD-L1↓, TumCG↓,
290- ALA,  HCA,    A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results
- vitro+vivo, Melanoma, B16-F10
TumCG↓, OS↑,
291- ALA,  HCA,  MET,  Dicl,    Metabolic therapies inhibit tumor growth in vivo and in silico
- in-vivo, Melanoma, B16-F10 - in-vivo, Lung, LL/2 (LLC1) - in-vivo, Bladder, MBT-2
TumCG↓,
1024- Api,  CUR,    Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects
- vitro+vivo, Melanoma, A375 - in-vitro, Melanoma, A2058 - in-vitro, Melanoma, RPMI-7951
TumCG↓, Apoptosis↑, PD-L1↓, STAT1↓, tumCV↓, T-Cell↑,
5387- AsP,  PacT,    Ascorbyl palmitate-incorporated paclitaxel-loaded composite nanoparticles for synergistic anti-tumoral therapy
- in-vivo, Melanoma, B16-F10
Dose↝, TumCG↓, TumCP↓, BioAv↓, BioAv↑, other↑, Apoptosis↑, Bax:Bcl2↑, EPR↑, toxicity↝,
2291- Ba,  BA,    Baicalein and Baicalin Promote Melanoma Apoptosis and Senescence via Metabolic Inhibition
- in-vitro, Melanoma, SK-MEL-28 - in-vitro, Melanoma, A375
LDHA↓, ENO1↓, PKM2↓, GLUT1↓, GLUT3↓, HK2↓, PFK1↓, GPI↓, TPI↓, GlucoseCon↓, TumCG↓, TumCP↓, mTORC1↓, Hif1a↓, Ki-67↓,
5587- BetA,  Rad,    Effects of betulinic acid alone and in combination with irradiation in human melanoma cells
- in-vitro, Melanoma, NA
TumCG↓, RadioS↑, Apoptosis↑, selectivity↑,
5924- CA,    Carnosic acid impedes cell growth and enhances anticancer effects of carmustine and lomustine in melanoma
- vitro+vivo, Melanoma, B16-F10
TumCG↓, TumCCA↑, P21↑, eff↑, AST↓, ALAT↓,
5920- Cats,    Treatment with Uncaria tomentosa Promotes Apoptosis in B16-BL6 Mouse Melanoma Cells and Inhibits the Growth of B16-BL6 Tumours
- in-vivo, Melanoma, B16-BL6
eff↑, Ki-67↓, TumCP↓, Apoptosis↑, TumCG↓,
1574- Citrate,    Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway
- in-vitro, Lung, A549 - in-vitro, Melanoma, WM983B - in-vivo, NA, NA
TumCG↓, eff↑, T-Cell↑, p‑IGF-1R↓, p‑Akt↓, PTEN↑, p‑eIF2α↑, OCR↓, ROS↓, ECAR∅, IL1↑, TNF-α↑, IL10↑, IGF-1R↓, eIF2α↑, PTEN↑, TCA↓, Glycolysis↓, selectivity↑, *toxicity∅, Dose∅,
1859- dietFMD,  Chemo,    Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity
- in-vitro, BC, 4T1 - in-vivo, Melanoma, B16-BL6
CLP↑, CD8+↑, TumCG↓, HO-1↓, TILs↑,
5010- DSF,  Cu,  Rad,    Disulfiram/Copper Combined with Irradiation Induces Immunogenic Cell Death in Melanoma
- in-vivo, Melanoma, B16-F10
Apoptosis↑, ICD↑, HMGB1↑, ATP↓, TumCG↓,
5013- DSF,  Cu,  Z,    Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease
- vitro+vivo, Melanoma, NA - Case Report, Melanoma, NA
P-gp↓, NF-kB↓, ChemoSen↑, angioG↓, TumCG↓, TumMeta↓, Remission↑, toxicity↓, ATF2↓, CREB↓, cycA1/CCNA1↓, TumCG↓, angioG↓, Dose↝, toxicity↝,
947- GA,    Gallic acid, a phenolic compound, exerts anti-angiogenic effects via the PTEN/AKT/HIF-1α/VEGF signaling pathway in ovarian cancer cells
- in-vitro, Ovarian, OVCAR-3 - in-vitro, Melanoma, A2780S - in-vitro, Nor, IOSE364 - Human, NA, NA
TumCG↓, VEGF↓, angioG↓, p‑Akt↓, Hif1a↓, PTEN↑, BioAv↑, *toxicity↓,
1961- GamB,    Effects of gambogic acid on the activation of caspase-3 and downregulation of SIRT1 in RPMI-8226 multiple myeloma cells via the accumulation of ROS
- in-vitro, Melanoma, RPMI-8226
TumCG↓, Apoptosis↑, ROS↑, Casp3↑, cl‑PARP↑, SIRT1↓, eff↓,
2918- LT,    Luteolin inhibits melanoma growth in vitro and in vivo via regulating ECM and oncogenic pathways but not ROS
- in-vitro, Melanoma, A375 - in-vivo, Melanoma, NA - in-vitro, Melanoma, SK-MEL-28
TumCG↓, ROS↑, ECM/TCF↓,
538- MF,    The extremely low frequency electromagnetic stimulation selective for cancer cells elicits growth arrest through a metabolic shift
- in-vitro, BC, MDA-MB-231 - in-vitro, Melanoma, MSTO-211H
TumCG↓, Ca+2↑, COX2↓, ATP↑, MMP↑, ROS↑, OXPHOS↑, mitResp↑,
526- MF,    Inhibition of Cancer Cell Growth by Exposure to a Specific Time-Varying Electromagnetic Field Involves T-Type Calcium Channels
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vitro, Pca, HeLa - vitro+vivo, Melanoma, B16-BL6 - in-vitro, Nor, HEK293
TumCG↓, Ca+2↑, selectivity↑, *Ca+2∅, ROS↑, HSP70/HSPA5↑, AntiCan↑,
220- MFrot,  MF,    Effect of low frequency magnetic fields on melanoma: tumor inhibition and immune modulation
- in-vitro, Melanoma, B16-F10
OS↑, DCells↑, T-Cell↑, Apoptosis↑, IL1↑, IFN-γ↓, IL10↑, TumCG↓, ROS↑, TumCP↓, TumCCA↑, ChrMod↑, CXCL9↓, CXCL12↓, CD4+↑, CD8+↑,
5162- PLB,    Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells
- vitro+vivo, Melanoma, A172
TumCG↓, TumCCA↑, Apoptosis↑, P21↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDC2↓, CDC25↑, Bax:Bcl2↑, Casp9↑, ROS↑, JNK↑, ERK↑, eff↓,
5032- PTS,    Pterostilbene Decreases the Antioxidant Defenses of Aggressive Cancer Cells In Vivo: A Physiological Glucocorticoids- and Nrf2-Dependent Mechanism
- in-vivo, Melanoma, NA
TumCG↓, NRF2↓, GR↓, BBB↑, ACTH↓, eff↑,
3054- RES,    Resveratrol induced reactive oxygen species and endoplasmic reticulum stress-mediated apoptosis, and cell cycle arrest in the A375SM malignant melanoma cell line
- in-vitro, Melanoma, A375
TumCG↓, P21↑, p27↑, CycB/CCNB1↓, ROS↑, ER Stress↑, p‑p38↑, P53↑, p‑eIF2α↑, EP4↑, CHOP↑, Bcl-2↓, BAX↓, TumCCA↑, NRF2↓, ChemoSen↑, GSH↓,
5337- TFdiG,    Theaflavin 3,3'-digallate suppresses metastasis and reduces insulin-like growth factor-1-induced cancer stemness and invasiveness in human melanoma cells
- in-vitro, Melanoma, A375 - in-vitro, Melanoma, A2058
TumCMig↓, TumCI↓, MMPs↓, ALDH↓, CSCs↓, ABCG2↓, CD44↓, CXCR4↓, TumCG↓, angioG↓, TumMeta↓,
1840- VitK2,    The mechanisms of vitamin K2-induced apoptosis of myeloma cells
- in-vitro, Melanoma, NA
TumCG↓, Apoptosis↑, Casp3↑, ROS↑, p‑MAPK↑,
1834- VitK3,  PDT,    Effects of Vitamin K3 Combined with UVB on the Proliferation and Apoptosis of Cutaneous Squamous Cell Carcinoma A431 Cells
- in-vitro, Melanoma, A431
eff↑, TumCG↓, TumCP↓, ROS↑, MMP↓,

Showing Research Papers: 1 to 25 of 25

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 25

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↓, 1,   HO-1↓, 1,   ICD↑, 1,   NRF2↓, 2,   OXPHOS↑, 1,   ROS↓, 1,   ROS↑, 9,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   ATP↑, 1,   CDC2↓, 1,   CDC25↑, 1,   mitResp↑, 1,   MMP↓, 1,   MMP↑, 1,   OCR↓, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   CREB↓, 1,   ECAR∅, 1,   ENO1↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 1,   GPI↓, 1,   HK2↓, 1,   LDHA↓, 1,   PFK1↓, 1,   PKM2↓, 1,   SIRT1↓, 1,   TCA↓, 1,   TPI↓, 1,  

Cell Death ⓘ

p‑Akt↓, 2,   Apoptosis↑, 9,   ATF2↓, 1,   BAX↓, 1,   Bax:Bcl2↑, 2,   Bcl-2↓, 1,   Casp3↑, 2,   Casp9↑, 1,   JNK↑, 1,   p‑MAPK↑, 1,   p27↑, 1,   p‑p38↑, 1,  

Transcription & Epigenetics ⓘ

ChrMod↑, 1,   other↑, 1,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   eIF2α↑, 1,   p‑eIF2α↑, 2,   ER Stress↑, 1,   HSP70/HSPA5↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

cycA1/CCNA1↓, 2,   CycB/CCNB1↓, 2,   P21↑, 3,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State ⓘ

ALDH↓, 1,   BMI1↓, 1,   CD133↓, 1,   CD44↓, 1,   CSCs↓, 2,   EP4↑, 1,   ERK↑, 1,   IGF-1R↓, 1,   p‑IGF-1R↓, 1,   mTORC1↓, 1,   PTEN↑, 3,   STAT1↓, 1,   TumCG↓, 26,  

Migration ⓘ

Ca+2↑, 2,   CXCL12↓, 1,   Ki-67↓, 2,   MMPs↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 5,   TumMeta↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   ECM/TCF↓, 1,   EPR↑, 1,   Hif1a↓, 2,   VEGF↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,   GLUT1↓, 1,   GLUT3↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD4+↑, 1,   CLP↑, 1,   COX2↓, 1,   CXCL9↓, 1,   CXCR4↓, 1,   DCells↑, 1,   HMGB1↑, 1,   IFN-γ↓, 1,   IL1↑, 2,   IL10↑, 2,   NF-kB↓, 1,   PD-L1↓, 2,   T-Cell↑, 3,   TILs↑, 1,   TNF-α↑, 1,  

Hormonal & Nuclear Receptors ⓘ

ACTH↓, 1,   GR↓, 1,  

Drug Metabolism & Resistance ⓘ

ABCG2↓, 1,   BioAv↓, 1,   BioAv↑, 2,   ChemoSen↑, 2,   Dose↝, 2,   Dose∅, 1,   eff↓, 2,   eff↑, 5,   RadioS↑, 1,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   Ki-67↓, 2,   PD-L1↓, 2,  

Functional Outcomes ⓘ

AntiCan↑, 1,   OS↑, 2,   Remission↑, 1,   toxicity↓, 1,   toxicity↝, 2,  

Infection & Microbiome ⓘ

CD8+↑, 2,  
Total Targets: 122

Pathway results for Effect on Normal Cells:


Migration ⓘ

Ca+2∅, 1,  

Functional Outcomes ⓘ

toxicity↓, 1,   toxicity∅, 1,  
Total Targets: 3

Scientific Paper Hit Count for: TumCG, Tumor cell growth
3 Magnetic Fields
2 Alpha-Lipoic-Acid
2 HydroxyCitric Acid
2 Radiotherapy/Radiation
2 Disulfiram
2 Copper and Cu NanoParticles
1 Astragalus
1 Metformin
1 Diclofenac
1 Apigenin (mainly Parsley)
1 Curcumin
1 Ascorbyl Palmitate
1 Paclitaxel
1 Baicalein
1 Baicalin
1 Betulinic acid
1 Carnosic acid
1 Cat’s Claw
1 Citric Acid
1 diet FMD Fasting Mimicking Diet
1 Chemotherapy
1 Zinc
1 Gallic acid
1 Gambogic Acid
1 Luteolin
1 Magnetic Field Rotating
1 Plumbagin
1 Pterostilbene
1 Resveratrol
1 Aflavin-3,3′-digallate
1 Vitamin K2
1 VitK3,menadione
1 Photodynamic Therapy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:39  Cells:%  prod#:%  Target#:323  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page